☞ 【POINT】 FDA Clinical Results “Large-scale Technology Export” Pharmaceutical Stocks (Click)
The biopharmaceutical market is expected to grow annually by 7-8% due to population aging and advancements in life sciences and medical technology, reaching a market size of $275 billion (KRW 300 trillion) by 2020.
Accordingly, a silent war has begun among major domestic and international corporations to dominate the Bio market.
Among them, the Alzheimer’s market alone was estimated to be $80 billion (KRW 82.6 trillion) annually as of 2017, and is projected to exceed $130 billion (KRW 153.4 trillion) by 2020.
In particular, according to “this company,” clinical phase 2 results have been announced showing that Lycium chinense (gugija) accumulates amyloid beta, which kills nerve cells, and can improve Alzheimer-type dementia, attracting industry attention.
☞ 【POINT】 Core Bio Stocks to Penetrate the US Market (Click)
Additionally, regarding the company and this matter, the anti-dementia drug demonstrated 40% superior ability to improve beta-amyloid deposition compared to existing synthetic dementia drugs, 20% better performance in spatial cognition tests, and an impressive 30% higher neuroregeneration capability.
“This treatment” is currently negotiating a large-scale technology transfer contract with a multinational pharmaceutical company.
Market participants are encouraged to receive stocks with high growth potential through the provided link.
Today's Stocks of Interest
#Uno&Company #Etron #JinwonLifeScience #HansolHomeDeco #Bioneer
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
